PNC-27 by Hudson Science. Studied for its ability to selectively target cancer cells while leaving healthy cells unaffected. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDependent on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
PNC-27 is a synthetic membrane active peptide derived from the HDM-2 binding domain of p53 (amino acids 12-26), linked to a transmembrane penetrating leader sequence from the Drosophila antennapedia homeodomain protein. Originally developed using a supercomputer at SUNY Downstate Medical Center in 2000, PNC-27 interacts with the MDM2 p53 tumor suppressor complex, acting as a competitive inhibitor to increase the half-life of p53 and facilitate the elimination of cancer cells. Hudson Science’s formulation supplies 10mg as a lyophilized vial, preserving peptide structural integrity across storage conditions until reconstitution.
PNC-27’s mechanism of action involves binding to the HDM-2 protein, which is overexpressed in many cancer cell membranes by binding to membrane bound HDM-2, PNC-27 creates oligomeric pores in the cancer cell plasma membrane, leading to cancer cell necrosis through membrane lysis. A notable aspect of PNC-27’s research profile is its ability to induce tumor cell necrosis independently of the p53 pathway. A significant characteristic because many cancer cells have compromised or mutated p53 which can render other treatments less effective, making PNC-27’s p53 independent action a research differentiator applicable to a wider range of tumor types.
Untransformed or non cancerous cells do not appear to form oligomeric pores when exposed to PNC-27, with research suggesting this selectivity is caused by MDM2’s mis localization to cancerous cell plasma membranes. This selective activity profile has generated significant research interest in PNC-27 as a tool compound for studying cancer cell membrane biology, HDM-2 expression patterns across tumor types, and the p53 independent mechanisms of tumor cell elimination. PNC-27’s evidence base remains predominantly preclinical; it is not an approved cancer treatment and human clinical data is limited at this stage of research.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched in comparative cancer cell membrane biology and tumor suppressor pathway studies. Browse CSD’s full peptide range for complete sourcing.
